Response
Dr Auer and colleagues suggest that on the basis of the results of the Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT), one should conclude that the class of angiotensin receptor antagonists is less effective than are angiotensin-converting enzyme (ACE) inhibitors in the treatment of congestive heart failure in patients taking ␤-blockers. I do not think that the results of these 2 studies allow such a conclusion.
In the ELITE II study, the number of patients included in the ␤-blocker subgroup analysis was small. 1 Thus, as stated by Pitt and colleagues, 1 "the interaction should be interpreted with caution." Furthermore, the dose of losartan used in this study was low (50 mg) and certainly insufficient to block the renin-angiotensin system for 24 hours. 2 Therefore, one cannot exclude the possibility that a higher dose of losartan would be as effective as an ACE inhibitor, even in patients receiving ␤-blockers.
With regard to the Val-HeFT study, 3 several points should be taken into account. First, the results have not yet been published. It is difficult, therefore, to discuss the data in much detail. Second, the goal of Val-HeFT was not to compare the efficacy of an ACE inhibitor with that of an angiotensin II receptor antagonist but rather to evaluate the potential benefits of valsartan administered in addition to an ACE inhibitor. Third, to my knowledge, the randomization was not stratified on the basis of the concurrent use of ␤-blockers. Thus, there may be potential bias related to the reasons for administering ␤-blockers. Taken together, the results of Val-HeFT do not provide any solid information regarding the comparative efficacy of ACE inhibitors and angiotensin II receptor antagonists in patients with congestive heart failure who are being treated with ␤-blockers. It is important to mention, however, that in ACE-intolerant patients, valsartan was remarkably effective, which clearly indicates that heart failure patients can benefit from angiotensin II receptor blockade. With regard to the potential interaction between the use of ␤-blockers and the effects of angiotensin II receptor antagonists, specific studies should be designed to answer the question. In the meantime, I would not recommend the avoidance of angiotensin II receptor blockers in heart failure patients who are being treated with ␤-blockers.
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